Terra Nova Asset Management LLC lifted its position in shares of Zoetis Inc (NYSE:ZTS) by 15.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,130 shares of the company’s stock after purchasing an additional 1,330 shares during the period. Terra Nova Asset Management LLC’s holdings in Zoetis were worth $730,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Zoetis during the 4th quarter worth $108,000. Icon Wealth Partners LLC purchased a new stake in Zoetis in the fourth quarter valued at $127,000. Steward Partners Investment Advisory LLC purchased a new stake in Zoetis in the third quarter valued at $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in Zoetis by 251.9% in the third quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after acquiring an additional 1,360 shares during the last quarter. Finally, Advisory Services Network LLC lifted its position in Zoetis by 42.4% in the fourth quarter. Advisory Services Network LLC now owns 2,423 shares of the company’s stock valued at $175,000 after acquiring an additional 721 shares during the last quarter. 91.53% of the stock is owned by institutional investors and hedge funds.
In other Zoetis news, insider Heidi C. Chen sold 37,453 shares of Zoetis stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $81.02, for a total value of $3,034,442.06. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Roman Trawicki sold 23,885 shares of the business’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $82.00, for a total transaction of $1,958,570.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 97,001 shares of company stock worth $7,882,428. 0.31% of the stock is currently owned by company insiders.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 15th. The company reported $0.69 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.03. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.40 billion. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. Zoetis’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.47 earnings per share. equities research analysts anticipate that Zoetis Inc will post 3.04 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, April 20th will be paid a $0.126 dividend. The ex-dividend date is Thursday, April 19th. This represents a $0.50 dividend on an annualized basis and a yield of 0.60%. Zoetis’s dividend payout ratio is presently 28.57%.
A number of equities research analysts recently weighed in on the stock. BMO Capital Markets set a $78.00 price target on shares of Zoetis and gave the company a “hold” rating in a research report on Thursday, February 15th. Piper Jaffray Companies set a $88.00 price target on shares of Zoetis and gave the company a “buy” rating in a research report on Friday, February 16th. Cantor Fitzgerald set a $85.00 price target on shares of Zoetis and gave the company a “buy” rating in a research report on Tuesday, January 2nd. UBS Group reissued a “neutral” rating on shares of Zoetis in a research report on Friday, November 24th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $86.00 price target (up from $84.00) on shares of Zoetis in a research report on Friday, February 16th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the stock. Zoetis currently has an average rating of “Buy” and a consensus target price of $80.28.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://sportsperspectives.com/2018/03/11/zoetis-inc-zts-stake-raised-by-terra-nova-asset-management-llc.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.